
Quarterly report 2025-Q3
added 11-06-2025
Inogen Cash Flow 2011-2026 | INGN
Annual Cash Flow Inogen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
5.91 M | -3.23 M | -37.5 M | 23.6 M | 37 M | 40.6 M | 60 M | 60.5 M | 31 M | - | - | - | - | - |
Depreciation & Amortization |
21 M | 18.2 M | 23.5 M | 21.6 M | 18.6 M | 13.8 M | 11.3 M | 12.3 M | 13.6 M | 14 M | 12.1 M | 8.54 M | 4.98 M | 298 K |
Accounts Payables |
16.6 M | 13.5 M | 18.2 M | 10.3 M | 12.5 M | 16.4 M | 13.7 M | 9.54 M | 5.74 M | 7.45 M | - | - | - | - |
Accounts Receivables |
29.6 M | 42.2 M | 62.7 M | 24.5 M | 29.7 M | 34.3 M | 37 M | 31.4 M | 30.8 M | 19.9 M | 19.3 M | - | - | - |
Total Inventories |
24.8 M | 21.8 M | 34.1 M | 31.9 M | 24.8 M | 35.7 M | 27.1 M | 18.8 M | 14.3 M | 8.65 M | 7.62 M | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Inogen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | - | -16.8 M | - | - | - | -4.75 M | - | - | - | -6.3 M | - | -22 M | - | -18.1 M | - | 17.1 M | - | 2.86 M | - | 20.8 M | 14.1 M | 540 K | - | 31.2 M | 16.6 M | -1.82 M | - | 47.6 M | 33.3 M | 12.2 M | - | 47.5 M | 30.1 M | - | - | - | - | - | - | - | - | - | - | - | - | -1.33 M | - | - | 6.88 M | 2.69 M | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
3.93 M | 4.01 M | 5.19 M | - | 4.21 M | 4.16 M | 5.26 M | - | 4.41 M | 4.26 M | 4.09 M | - | 3.78 M | 3.7 M | 5.76 M | - | 15.9 M | 3.04 M | 5.1 M | - | 13.7 M | 8.94 M | 4.46 M | - | 9.22 M | 5.55 M | 2.79 M | - | 8.52 M | 5.81 M | 2.99 M | - | 9.26 M | 6.32 M | 3.2 M | - | 10.3 M | 6.87 M | 3.45 M | - | 10.5 M | 6.91 M | 3.44 M | - | 8.78 M | 5.59 M | 2.66 M | - | 6 M | 3.65 M | 1.66 M | - | - | - | - | - | - | - | - |
Accounts Payables |
21.2 M | 21.9 M | 23.3 M | 16.6 M | 15.5 M | 15 M | 15.9 M | 13.5 M | 15.4 M | 13.4 M | 18 M | 18.2 M | 21.5 M | - | 18.1 M | 10.3 M | 15.9 M | 15.6 M | 14.6 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 13.7 M | 13.7 M | 13.7 M | 13.7 M | 9.54 M | 9.54 M | 9.54 M | 9.54 M | 5.74 M | 5.74 M | 5.74 M | 5.74 M | 7.45 M | 7.45 M | 7.45 M | 7.45 M | 6.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
40.4 M | 38.6 M | 36.6 M | 29.6 M | 34.2 M | 36 M | 40.2 M | 42.2 M | 48.4 M | 51.1 M | 53.9 M | 62.7 M | 50.5 M | - | 34 M | 24.5 M | 32.9 M | 36.9 M | 38.4 M | 29.7 M | 29.7 M | 29.7 M | 29.7 M | 34.3 M | 34.3 M | 34.3 M | 34.3 M | 37 M | 37 M | 37 M | 37 M | 31.4 M | 31.4 M | 34.8 M | 31.4 M | 30.8 M | 30.8 M | 30.8 M | 30.8 M | 19.9 M | 19.9 M | 19.9 M | 19.9 M | 19.3 M | 19.3 M | 19.3 M | 19.3 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | - | - | - | - | - | - | - | - |
Total Inventories |
25.1 M | 24.3 M | 26.3 M | 24.8 M | 23.3 M | 24 M | 24.6 M | 21.8 M | 24 M | 30.7 M | 38.8 M | 34.1 M | 35.7 M | - | 34.1 M | 31.9 M | 31.8 M | 27.2 M | 26.4 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 35.7 M | 35.7 M | 35.7 M | 35.7 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 8.65 M | 8.65 M | 8.65 M | 8.65 M | 7.62 M | 7.62 M | 7.62 M | 7.62 M | 4.25 M | 4.25 M | 4.25 M | 4.25 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Inogen, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical devices sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
AxoGen
AXGN
|
$ 33.22 | 1.87 % | $ 1.47 B | ||
|
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | ||
|
Apollo Endosurgery
APEN
|
- | - | $ 475 M | ||
|
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | ||
|
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | ||
|
Aziyo Biologics
AZYO
|
- | 1.37 % | $ 20.5 M | ||
|
Cognyte Software Ltd.
CGNT
|
$ 7.01 | 2.04 % | $ 503 M | ||
|
Apyx Medical Corporation
APYX
|
$ 3.76 | -1.7 % | $ 130 M | ||
|
Alphatec Holdings
ATEC
|
$ 13.29 | 1.41 % | $ 1.9 B | ||
|
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | ||
|
Bio-Rad Laboratories
BIO
|
$ 255.19 | -12.51 % | $ 7.2 B | ||
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
Bruker Corporation
BRKR
|
$ 36.35 | -3.09 % | $ 5.42 K | ||
|
BioSig Technologies
BSGM
|
- | 37.08 % | $ 85.7 M | ||
|
CONMED Corporation
CNMD
|
$ 41.59 | -0.28 % | $ 1.28 B | ||
|
Boston Scientific Corporation
BSX
|
$ 74.77 | 0.88 % | $ 110 B | ||
|
Abbott Laboratories
ABT
|
$ 112.22 | 0.66 % | $ 195 B | ||
|
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | ||
|
EDAP TMS S.A.
EDAP
|
$ 4.8 | 0.63 % | $ 179 M | ||
|
Delcath Systems
DCTH
|
$ 9.25 | 1.43 % | $ 264 M | ||
|
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | ||
|
ClearPoint Neuro
CLPT
|
$ 13.44 | 3.07 % | $ 363 M | ||
|
Electromed
ELMD
|
$ 24.2 | 3.82 % | $ 205 M | ||
|
Dynatronics Corporation
DYNT
|
- | 14.99 % | $ 929 K | ||
|
Neovasc
NVCN
|
- | - | $ 111 M | ||
|
Eargo
EAR
|
- | - | $ 10.2 M | ||
|
InMode Ltd.
INMD
|
$ 14.36 | 0.38 % | $ 1.14 B | ||
|
IRadimed Corporation
IRMD
|
$ 99.81 | -0.03 % | $ 1.26 B | ||
|
GBS
GBS
|
- | -0.57 % | $ 7.12 M | ||
|
Integer Holdings Corporation
ITGR
|
$ 85.46 | 0.23 % | $ 2.87 B | ||
|
Second Sight Medical Products
EYES
|
- | -0.97 % | $ 54.4 M | ||
|
Penumbra
PEN
|
$ 339.82 | 0.32 % | $ 13.1 B | ||
|
Avinger
AVGR
|
- | -20.74 % | $ 369 K | ||
|
FONAR Corporation
FONR
|
$ 18.55 | 0.05 % | $ 122 M | ||
|
Pulmonx Corporation
LUNG
|
$ 1.47 | 3.17 % | $ 57.5 M | ||
|
Globus Medical
GMED
|
$ 87.89 | 0.76 % | $ 11.9 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
$ 11.29 | 4.46 % | $ 869 M | ||
|
Myomo
MYO
|
$ 0.82 | 0.41 % | $ 5.78 M | ||
|
Establishment Labs Holdings
ESTA
|
$ 75.22 | 2.28 % | $ 2.12 B |